Standout Papers

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with pso... 2013 2026 2017 2021 640
  1. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial (2015)
    Iain B. McInnes, Philip J. Mease et al. The Lancet
  2. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial (2013)
    Iain B. McInnes, Arthur Kavanaugh et al. The Lancet
  3. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial (2014)
    Christopher T. Ritchlin, Proton Rahman et al. Annals of the Rheumatic Diseases
  4. Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey (2014)
    Mark Lebwohl, H. Bachelez et al. Journal of the American Academy of Dermatology
  5. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor (2014)
    Arthur Kavanaugh, Philip J. Mease et al. Annals of the Rheumatic Diseases
  6. Psoriatic arthritis (2021)
    Oliver FitzGerald, Alexis Ogdie et al. Nature Reviews Disease Primers

Immediate Impact

13 from Science/Nature 78 standout
Sub-graph 1 of 17

Citing Papers

GZMK-expressing CD8+ T cells promote recurrent airway inflammatory diseases
2025 StandoutNature
Dictionary of immune responses to cytokines at single-cell resolution
2023 StandoutNature
12 intermediate papers

Works of Arthur Kavanaugh being referenced

Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis
2015
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
2013 Standout
and 7 more

Author Peers

Author Last Decade Papers Cites
Arthur Kavanaugh 8542 7984 4789 309 12.1k
Proton Rahman 7370 6636 3378 308 10.6k
Peter Nash 7217 5052 3708 342 11.1k
Filip Van den Bosch 8534 5191 3463 298 10.6k
Oliver FitzGerald 8496 6702 3792 468 14.2k
Atul Deodhar 6572 4813 2776 297 8.8k
Christopher T. Ritchlin 9763 9281 5243 342 14.7k
Herman Mielants 8409 4812 3209 215 10.6k
Xenofon Baraliakos 13547 7258 4492 570 15.3k
Joachim Listing 12192 6011 4618 178 14.4k
Kimme L Hyrich 7420 3114 3750 312 11.8k

All Works

Loading papers...

Rankless by CCL
2026